This chemo-enzymatic peptide synthetic technology offers an entry into economic manufacturing processes for linear peptide drugs and small proteins. The potential of the peptiligase technology however extends far beyond linear peptides and small proteins, to areas such as macrocycles (cyclotides), antibody-drug conjugates and conjugated dual inhibitors. The enzyme does not need a specific sequence of amino acids for the recognition and does not require modifications in the sequence to make it work. Furthermore, it is highly efficient and very well scalable to kg-scale. In this poster, we’ll share several cases showing longer peptide and small protein syntheses using this technology.